Coherus Oncology, Inc.
Coherus Oncology, Inc. (CHRS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CHRS · as of Sep 30, 2025
Ownership Breakdown
121
Institutional Holders
▲ 5 vs Q2
$84.72M
Total Inst. Value
▲ $44.28M vs Q2
122.41M
Shares Outstanding
freeFloat 94.87%
51.67M
13F Shares Held
▼ 3.69M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CHRS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 10.46M | 9.01% | 9.01% | $17.15B | Nov 12, 2025 | ▼ 279.7K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 10.32M | 8.89% | 8.89% | $16.93B | Nov 7, 2025 | ▼ 249.4K |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 5.10M | 4.39% | 4.39% | $8.36B | Nov 14, 2025 | — held |
KOHLBERG KRAVIS ROBERTS & CO. L.P. biological products, (no diagnostic substances) | 3.04M | 2.62% | 2.62% | $4.93B | Nov 14, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.74M | 2.36% | 2.36% | $4.50B | Nov 12, 2025 | ▲ 64.8K |
STATE STREET CORP biological products, (no diagnostic substances) | 2.22M | 1.92% | 1.92% | $3.65B | Nov 14, 2025 | ▲ 4.8K |
CM MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.10M | 1.81% | 1.81% | $3.44B | Nov 13, 2025 | ▼ 150.0K |
C WORLDWIDE GROUP HOLDING A/S biological products, (no diagnostic substances) | 1.93M | 1.66% | 1.66% | $3.16B | Nov 5, 2025 | — held |
PANAGORA ASSET MANAGEMENT INC biological products, (no diagnostic substances) | 1.38M | 1.19% | 1.19% | $2.26B | Nov 13, 2025 | ▲ 581.6K |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC biological products, (no diagnostic substances) | 993.1K | 85.55% | 85.55% | $1.63B | Nov 10, 2025 | ▲ 11.7K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
26
Increased
+2.01M shares2
New Positions
first time holders14
Decreased
−1.86M shares0
Sold Out
fully exitedNet shares change (top 50)
+150.7K
+2.01M / −1.86M
Net new holders
+14
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CHRS insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
2
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
McMichael Bryan J Chief Financial Officer | May 29, 2026 | Award | 100,000 | $1.59 | $159.0K | 100.0K | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | Award | 30,000 | $1.59 | $47.7K | 30.0K | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | Award | 25,000 | $1.59 | $39.8K | 25.0K | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | Award | 15,000 | $1.59 | $23.9K | 15.0K | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | D-Return | 100,000 | $14.76 | $1.48M | 0 | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | D-Return | 25,000 | $14.67 | $366.8K | 0 | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | D-Return | 15,000 | $10.78 | $161.7K | 0 | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | D-Return | 25,000 | $9.87 | $246.7K | 0 | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | D-Return | 25,000 | $6.00 | $150.0K | 0 | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | D-Return | 30,000 | $5.44 | $163.2K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Coherus Oncology, Inc. (CHRS) is primarily owned by institutional investors, who hold approximately 42.2% of total shares outstanding. Company insiders own approximately 5.13%, while retail and public investors account for the remaining 52.65%.
The largest institutional shareholder of Coherus Oncology, Inc. is BLACKROCK, INC., holding approximately 10.46 million shares — equal to 9.01% of outstanding shares — as of September 30, 2025.
A total of 121 institutional investors currently hold CHRS stock, with a combined institutional value of approximately $84,724,926 as of the most recent 13F filing period.
Frequently asked questions
CHRS ownershipCoherus Oncology, Inc. (CHRS) is primarily owned by institutional investors, who hold approximately 42.2% of shares. The largest shareholder is BLACKROCK, INC. with a 9.01% stake. Company insiders hold 5.13%. Data sourced from SEC Form 13F as of September 30, 2025.